ĀÜĄņĀŅĀ×

Kyle Kingma has been the top finance executive at EMulate since 2010. He brings over 15 years of experience in the finance sector with over 10 years as the senior finance professional at EMulate Therapeutics. Kyle is accomplished in leading finance and operational teams to help guide a company from startup stage through IPO readiness. Kyle has designed, implemented and maintained systems that integrate company goals and objectives into finance, information technology, operations and business development. Kyle oversaw financial and partnering operations of EMulateā€™s first spin-out company, Hapbee Technologies (HAPB:TSXV) and was pivotal to the achievement of Hapbeeā€™s public listing. In his time at EMulate Therapeutics and working with Hapbee Technologies, Inc., he has managed and directed finances for over $80M in funds raised as well as over $5M in non-dilutive financing.

As the General Manager of EMulate Subsidiaries, Kyle coordinates outreach to strategic and investment partners in each of EMulateā€™s target sectors, with an initial focus on Cellsana Therapeutics (oncology), Indolor Therapeutics (pain management) and Mensana Therapeutics (mental health).

Kyle has spearheaded outreach to hundreds of companies, funds and advocacy groups, which has led to EMulateā€™s first federal grant submission, as well as multiple conversations with potential strategic and funding partners.

Kyle began his professional career in the audit practice at KPMG, where he gained wide experience with an array of clients, from startups to multinational public companies.